InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,686.00
(
0.23%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.31
(
-0.03%
)
Bitcoin
54,357.67
(
-4.60%
)
Post# of 252486
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 245574

Thursday, 05/18/2023 5:14:01 PM

Thursday, May 18, 2023 5:14:01 PM

Post# of 252486
VRBPAC endorses PFE’s maternal RSV vaccine:

https://www.businesswire.com/news/home/20230518005725/en

The votes were 14-0 for efficacy and 10-4 for safety. The “no” votes on safety were presumably due to a (non-statsig) higher rate of premature births in the vaccine arm than the placebo arm.

PFE’s RSV vaccine for adults and has a 5/31/23 PDUFA date, while PFE’s maternal RSV vaccine (the subject of today’s VRBPAC) has a PDUFA date in Aug 2023.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up